Chemotaxis of 3T3 and SV3T3 Cells to Fibronectin Is Mediated through the Cell-Attachment Site in Fibronectin and a Fibronectin Cell Surface Receptor

Adriana Albini,*† Gabriella Allavena,* Antonella Melchiori,* Filippo Giancotti,† Hartmut Richter,§ Paolo M. Comoglio,‡ Silvio Parodi,* George R. Martin,¶ and Guido Tarone*†

* Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; † Dipartimento di Scienze Biomediche ed Oncologia, Università di Torino, Torino, Italy; § Max Planck Institut für Biochemie, Martinsried, Federal Republic of Germany; ¶ Laboratory for Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892; ¶ Laboratory of Developmental Biology and Anomalies, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892

Abstract. Fibronectin (FN) is a multidomain extracellular matrix protein that induces attachment and chemotactic migration of fibroblastic cells. In this study we analyzed the molecular determinants involved in the FN-induced chemotactic migration of normal and SV40-transformed 3T3 cells. Two different monoclonal antibodies to the cell-binding site of FN blocked chemotaxis to a 140-kD FN fragment (Ca 140) containing the cell-binding domain. A monoclonal antibody to a determinant distant from the cell-binding site did not affect chemotaxis. A synthetic tetrapeptide, RGDS, which represents the major cell-attachment sequence, was able to compete with FN and the Ca 140 fragment in chemotaxis assays, but this peptide itself had no significant chemotactic activity. A larger peptide encompassing this sequence, GRGDSP, was chemotactic, while the peptide GRGESP, where a glutamic acid residue was substituted for aspartic acid, was inactive. Chemotactic migration could be prevented in a dose-dependent manner by a rabbit polyclonal antiserum to a 140-kD cell surface FN receptor. This antibody was more effective on normal than on transformed 3T3 cells. Neither the anti-FN receptor antiserum nor a monoclonal antibody to the cell-binding site of FN blocked migration induced by another potent chemoattractant, platelet-derived growth factor. These data indicate that FN-induced chemotaxis of 3T3 and SV3T3 cells is mediated via the RGDS cell-attachment site of FN and the 140-kD cell surface FN receptor. The interaction is specific and can be altered by transformation.

A number of studies indicate that fibronectin (FN)† and certain FN fragments are potent chemoattractants for fibroblastic cells (5, 17, 27, 34, 41, 44, 47). Presumably this activity is important in wound healing where fibroblasts from the surrounding tissues are recruited to the site of damage to produce the matrix molecules necessary for full repair (48). The rate of repair is believed to be related to the numbers of cells recruited to the wound site and thereby to the level of chemoattractants and the duration of their production. Chemotaxis to FN may also be involved in pathological situations including fibrosis and tumor cell metastasis (2, 22, 28, 30, 31, 44, 52–54). The chemotactic region of FN has been localized within a large cell-binding chymotryptic 160-kD peptide (47) and in a cathepsin D–derived 140-kD peptide which lacks gelatin-binding activity (3, 5, 41).

Materials and Methods

Cellular Material

3T3 cells and SV3T3 were kindly provided by Dr. P. Prehm (Max-Planck-Institut für Biochemie, Munich, FRG). Cells were cultivated in DME, supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (50 μg/ml),
and glutamine (300 μg/ml), and were harvested by trypsin treatment (0.05 % trypsin, 0.02 % EDTA in PBS, pH 7.4).

**Chemoattractants**

FN (Sigma, Munich, FRG) was diluted with DME to 30 μg/ml. Ca 140, a large cathepsin D fragment, was prepared from purified human plasma FN by mild digestion (45). The preparation, purification, and electrophoretic purity of the Ca 140 fragment has been previously described (16, 45). Ca 140 was shown previously to be a potent chemoattractant (3, 5) and was used here at 20 μg/ml. Platelet-derived growth factor (PDGF) was purchased from Collaborative Research, Inc. (Lexington, MA) and used as a chemoattractant at 5 ng/ml (46). The tetrapeptide RGDS was purchased from Nova Biochemical AG (Läwelfingen, Switzerland). The hexapeptides GRGDSP and GRGESP were synthesized by Prof. P. Neri of Centro di Ricerca Interdepartimentale per le Scienze Mediche Avanzate (CRISMA, University of Siena, Siena, Italy), using an automated peptide synthesizer (model No. 430A, Applied Biosystems, Inc., Foster City, CA) equipped with the chemistry provided by the manufacturer. After cleavage from the resin with hydrogen fluoride the peptides were purified by two cycles of chromatography on Sephadex G10 in water, lyophilized, and stored at -20 C.

**Antibodies**

A317 and A286 are two distinct monoclonal antibodies reacting with determinants within the COOH-terminus of peptide Ca 140 (16, 45). These antibodies were kindly provided by M. Schachner (Institut für Neurobiologie, Heidelberg, FRG). The monoclonal antibody 3E3, a gift of M. Pierschbacher (La Jolla Cancer Research Foundation, La Jolla, CA), reacts with the cell-attachment domain of FN (39). Goat anti–FN serum was a gift of Klaus von der Mark (Max-Planck-Institut, Martinsried, FRG). The anti–baby hamster kidney (BHK) serum reacting with the 140-kD FN receptor on BHK cells has been previously characterized (18, 19, 51). An IgG fraction from this serum was prepared by affinity chromatography on Protein A-Sepharose. Immunoprecipitation of the cell surface receptor proteins was performed as previously described (51). The 135-kD component of the FN receptor was purified from SR/BALB/c 3T3 cell membranes on lectin–Sepharose column followed by hydroxypatite chromatography (20). For some experiments the anti–BHK antiserum was adsorbed on a receptor affinity column.

**Chemotaxis Assays**

These assays were carried out in Boyden chambers as described previously (42). Cells were harvested in trypsin (0.05%) and EDTA (0.01%) in PBS (pH 7.4). The cells were recovered by centrifugation, resuspended in DME, recentrifuged, and then resuspended in DME without serum. Cells (1 × 10⁵) were added to the upper compartment (0.8 ml) of the Boyden chamber and the lower compartment (0.2 ml) was filled with media usually containing a chemoattractant, in the presence or absence of different antibodies.

### Table I. Inhibition of Chemotactic Activity of 3T3 Cells by Antibodies to the Cell-binding Site of FN

| Attractant | Antibody | Concentration (μg/ml) | Maximal activity (%) |
|------------|----------|----------------------|----------------------|
| FN         | –        | 0                    | 100 ± 22             |
| Ca 140     | A317     | 20                   | 69 ± 16              |
| Ca 140     | A317     | 40                   | 38 ± 3               |
| Ca 140     | A286     | 20                   | 84 ± 5               |
| Ca 140     | A286     | 40                   | 91 ± 6               |
| Ca 140     | 3E3      | 20                   | 38 ± 14              |
| PDGF       | –        | 0                    | 100 ± 8              |
| PDGF       | 3E3      | 20                   | 100 ± 15             |

We analyzed the effect of different monoclonal antibodies recognizing Ca 140 (which contains the cell-binding domain) on the migration of 3T3 cells to Ca 140 itself (20 μg/ml) and to PDGF (5 ng/ml). A317 and 3E3 are antibodies directed to the cell-binding site in Ca 140, while A286 recognizes a determinant in a more NH₂-terminal region of the fragment. Data are expressed as percent of maximal migration as compared to the chemoattractant alone. Experiments were run in triplicate and repeated twice. SDs are indicated.

**Results**

**Inhibition of Fibroblast Migration by Antibodies to the Cell-binding Site of FN**

It is well known that FN is a potent chemoattractant for fibroblastic cells and that the active region lies within a large fragment (Ca 140) which contains the major cell-binding domain of the molecule (38, 41, 47). The effect of three monoclonal antibodies which react with this fragment were tested (Table I). Monoclonals A317 and 3E3 react with the cell-binding site within Ca 140 while A286 recognizes a determinant in a more NH₂-terminal region of Ca 140 (16). Monoclonal antibodies A317 and 3E3 (Table I) as well as
Table II. Effect of Synthetic Peptides on Migration of 3T3 and SV3T3 Cells towards FN

| Attractant | Migrated cells |
|-----------|----------------|
| Lower compartment | Upper compartment |
| 3T3 | SV3T3 |
| FN | 7 ± 2 | 7 ± 2 |
| RGDS | 100 ± 1 | 100 ± 4 |
| GRGESP | 10 ± 2 | 7 ± 1 |
| | 6 ± 1 | 7 ± 1 |
| | FN | 7 ± 2 | 7 ± 4 |
| | RGDS | 10 ± 4 | 9 ± 4 |
| FN | 41 ± 2 | 49 ± 6 |
| RGDS | 14 ± 4 | ND |
| FN | 75 ± 2 | 32 ± 2 |
| FN | GRGESP | 102 ± 7 | 95 ± 9 |

For this experiment, chemoattractants were placed either in the lower or in the upper compartment of chemotaxis chambers. FN was used at 30 µg/ml. RGDS was used at the concentration exerting maximal activity in preliminary experiments; i.e., 200 µg/ml. GRGESP was used at the same concentration; other concentrations tested were inactive as well. Data are expressed as percent of maximal migration as compared to the chemoattractant alone. Experiments were run in triplicate and repeated three times. SDs are indicated.

Effect of Synthetic Peptides on Cell Migration

The sequence Arg-Gly-Asp-Ser (RGDS) has been identified as the major cell-binding domain of FN (37, 38, 40). The possibility that synthetic peptides containing this sequence were chemotactic or could inhibit FN-induced migration was investigated. RGDS alone in the lower compartment of the Boyden chamber at levels up to 1,000 µg/ml did not stimulate cell migration (Table II). In contrast, GRGDSP was found to elicit a dose-dependent response (Fig. 2). The response was biphasic with a peak of maximal activity observed between 10⁻³ and 10⁻² µM. A related peptide with glutamic acid substituted for aspartic acid was not chemotactic, nor did it exhibit competitive activity (Table II) at concentrations up to 1 mg/ml. When the RGDS peptide was added in the lower compartment of the Boyden chamber together with FN (Table II) or the Ca 140 peptide (Table III), a dose-dependent reduction of cell migration was observed. A reduction of FN-induced cell migration was also observed when RGDS was added to the upper compartment (Table II). In this case maximal activity was achieved with 200 µg/ml. SV3T3 cells were more responsive to the peptides than 3T3 cells (Table II). RGDS (Table II) stimulated random migration when added to both compartments. To see if the migration to GRGDSP was mostly chemotactic or chemokinetic, we ran a checkerboard analysis (57) using concentrations of the peptide active in stimulating migration. Table IV shows that the migration of cells in the presence of equimolar concentrations of the peptide (i.e., chemokinesis [values on the diagonal]) is lower than their migration when the peptide was present only in the lower compartment (chemotaxis), or only in the upper compartment. These experiments indicate that the RGDS cell-binding site is involved in 3T3 and SV3T3 cell chemotaxis to FN and in stimulated random migration.

Inhibition of Cell Migration by Antibodies to the FN Receptor

To investigate the role of cell surface proteins in the chemotactic response to FN, we used an antiserum (anti-BHK) that inhibits fibroblast attachment and spreading on FN-coated dishes (19). This antiserum was tested here for its ability to precipitate the FN receptor complex (18, 19). Under reducing conditions the precipitated material migrated as a diffuse band at Mr 140,000 (Fig. 3). In the absence of reducing agents, two major components are observed, with molecular masses of 150 and 135 kD, respectively (Fig. 3). Recent results (Tarone, G., and F. Giancotti, unpublished results) indicate that the two polypeptides are parts of a heterodimeric complex. When the anti-BHK antiserum was added to the lower compartment of the Boyden chamber, cell migration toward FN was inhibited in a dose-dependent manner (Fig. 4). The antibodies did not affect migration of cells towards PDGF, a potent chemoattractant (46) known to act as the major cell-binding domain of FN (37, 38, 40). The possibility that synthetic peptides containing this sequence were chemotactic or could inhibit FN-induced migration was investigated. RGDS alone in the lower compartment of the Boyden chamber at levels up to 1,000 µg/ml did not stimulate cell migration (Table II). In contrast, GRGDSP was found to elicit a dose-dependent response (Fig. 2). The response was biphasic with a peak of maximal activity observed between 10⁻³ and 10⁻² µM. A related peptide with glutamic acid substituted for aspartic acid was not chemotactic, nor did it exhibit competitive activity (Table II) at concentrations up to 1 mg/ml. When the RGDS peptide was added in the lower compartment of the Boyden chamber together with FN (Table II) or the Ca 140 peptide (Table III), a dose-dependent reduction of cell migration was observed. A reduction of FN-induced cell migration was also observed when RGDS was added to the upper compartment (Table II). In this case maximal activity was achieved with 200 µg/ml. SV3T3 cells were more responsive to the peptides than 3T3 cells (Table II). RGDS (Table II) stimulated random migration when added to both compartments. To see if the migration to GRGDSP was mostly chemotactic or chemokinetic, we ran a checkerboard analysis (57) using concentrations of the peptide active in stimulating migration. Table IV shows that the migration of cells in the presence of equimolar concentra-

Table III. Effect of the RGDS Peptide on the Migration of 3T3 Cells towards Ca 140

| Attractant | RGDS concentration | Migration |
|-----------|--------------------|----------|
|          | µg/ml              |          |
|          |                    | %        |
| Ca 140   | 0                  | 5 ± 1    |
| Ca 140   | 20                 | 100 ± 20 |
| Ca 140   | 200                | 81 ± 3   |
| Ca 140   | 1,000              | 52 ± 5   |

Ca 140 was used at concentrations of 20 µg/ml. Increasing concentrations of RGDS were used along with the chemotactic fragment in the lower compartment of Boyden chambers. Data are expressed as percent migration as compared to Ca 140. Experiments were run in triplicate and repeated twice. SDs are indicated.
Table IV. Checkerboard Analysis of GRGDSP Migration-inducing Activity for 3T3 Cells

| Lower compartment | Upper compartment |
|-------------------|------------------|
|                   | 0                | $10^{-3}$ μM | $10^{-1}$ μM |
| 0                 | 3 ± 2            | 9 ± 1        | 2 ± 1        |
| $10^{-3}$ μM      | 16 ± 2           | 3 ± 1        | 2 ± 1        |
| $10^{-1}$ μM      | 10 ± 2           | 2 ± 1        | 1 ± 0        |

Concentrations of GRGDSP active in chemotactic stimulation (Fig. 2) were put in the lower and/or upper compartment. The first column on the left represents chemotaxis, the diagonal represents chemokinetic activity.

through a different receptor (8, 24). Furthermore, adsorption of the antiserum with partially purified FN receptor resulted in the virtually complete loss of inhibitory activity on cell migration (data not shown). The possibility that antibodies inhibited migration by preventing adhesion of the cells to the upper surface of the filter was ruled out since a concentration of 250 μg/ml of antibodies in the lower compartment significantly inhibited migration (50%) without affecting adhesion (data not shown). The antibodies were found to be more effective in preventing FN-induced directional migration of normal than of SV40-transformed cells. As shown in Fig. 4, in fact, while 200 μg/ml gave ~50% inhibition of migration of normal 3T3 cells, an approximately twofold higher concentration of the antibodies was necessary to obtain the same degree of inhibition with SV3T3 cells.

**Discussion**

FN is a potent chemoattractant, particularly for mesenchymal cells, and chemotactic activity resides in a cathepsin D-derived fragment (Mr 140,000) (3, 5, 41, 47). When coated onto surfaces, this peptide also mediates cell attachment by binding to FN receptors on cell surfaces (5, 47). Current concepts suggest that chemotaxis is also a receptor-mediated phenomenon, which allows the cells to detect and migrate along a gradient of a chemotactic factor (2, 6, 12, 22, 24, 36, 49, 56). Due to the coincidence of attachment and chemotactic activities within the Ca 140 fragment of FN, it seemed possible that they represent different functions mediated via the same recognition system.

In the present work, we show that RGDS-containing FN sequences (37, 38, 40) and the 140-kD cell surface receptor (18, 19, 51) known to be involved in cell-substratum adhesion also mediate the migratory response of 3T3 and SV3T3 cells to FN and an FN fragment.

Two monoclonal antibodies (A317 and 3E3), able to block cell attachment by reacting with the portion of Ca 140 close to the cell-attachment site (16, 39), also inhibit the chemotactic response of the cells to the Ca 140 peptide. Moreover, the synthetic hexapeptide GRGDSP, corresponding to the cell-attachment sequence in FN (37, 38, 40), was able to stimulate both random and chemotactic migration, although its chemotactic activity is lower (i.e., 30%) than that of FN. A shorter peptide, RGDS, was not significantly chemotactic itself, but did reduce chemotaxis to the Ca 140 cell-binding peptide indicating that it can compete in FN-cell recognition. GRGDSP is also a better substrate for adhesion than RGDS (37). The loss of chemotactic activity of RGDS could...
FN-mediated cell adhesion appears to occur via cell receptors (1, 9, 11, 13, 15, 21, 23, 25, 35, 43, 50). Using antibodies to the FN receptor of mouse fibroblasts (18, 19, 51), we provided evidence for the involvement of this molecule in the chemotactic response to FN. These antibodies, in fact, strongly inhibited cell migration through the filter. Neither the antibodies to the cell-attachment site in FN nor the antibody to the FN receptor altered chemotaxis to PDGF under the same experimental conditions. This shows that the interactions with FN are specific and also that the general chemotactic ability of the cells to translocate on the filter and migrate directionally is not impaired by the anti-FN and anti-FN receptor antibodies. It is likely that the 3T3 cells can locomote via independent means to PDGF.

It is interesting to note that neither the anti-FN, the anti-FN receptor antibodies, nor the peptide completely inhibited the chemotactic response to FN. This suggests the involvement of other sites in FN which are active in the chemotactic stimulation of fibroblastic cells. The existence of adhesion-mediating sites on FN, different than the RGDS site, have been described (26, 31). Our Ca 140 peptide is localized 65-75 kD from the COOH-terminal end of the molecule. Therefore it contains the domains III and IV which have been investigated for adhesion and motility-promoting activities by McCarthy et al. (32), who suggest that an adhesion and motility-promoting site, in addition to RGDS (located in domain IV), are present in domain III.

Our results also indicate that both anti-FN and anti-FN receptor antibodies were less effective in preventing migration of SV3T3 cells than that of 3T3 cells. This is consistent with the fact that SV40-transformed cells display an enhanced chemotactic response to FN (3, 33). In contrast, SV3T3 were more sensitive than 3T3 cells to the inhibitory effect of the RGDS peptide. We conclude that, although the migration of 3T3 and SV40-transformed 3T3 cells involves the same molecular mechanisms, the response to FN, to anti-FN receptor antibody, and to FN peptide is somewhat altered in SV40-transformed cells. Perhaps this is related to the differences in distribution of FN receptor, which in normal cells are clustered in the adhesion plaques and in transformed fibroblasts have a diffuse distribution (18, 55). It is possible that the lack of clustering of FN receptors within localized membrane domains may contribute to the higher motility of transformed cells.

Preliminary observations that either antibodies to the FN receptor or synthetic peptides inhibit translocation on a matrix substrate were recently presented (4, 7, 10, 14, 29). It is not surprising that antibodies or peptides able to interfere with cell adhesion also prevent migration on a matrix substrate. Our work presents evidence that the cell-binding domain of FN and its receptor are involved in the chemotactic response of fibroblasts to a gradient of FN in solution.

In summary, our data show that the chemotaxis of 3T3 and SV3T3 cells is mediated through the RGDS cell attachment site of FN and through the FN cell surface receptor. The interaction is specific and there is preliminary evidence for its alteration with transformation.

We thank Dr. R. C. Ogle and Dr. H. K. Kleinman (National Institute of Dental Research/National Institutes of Health, Bethesda, MD) for helpful discussion. We are grateful to Dr. G. T. Kitten for critical reading of the manuscript. We acknowledge Drs. M. Pierschbacher, M. Schachner, and M. Dziadek for the gift of the antibodies. We thank Prof. P. Neri of the Department CRISMA of the University of Siena, Italy, for providing the synthetic peptides. The skillful technical assistance of Mrs. Ivana Brega is gratefully acknowledged.

This work was partially supported by grants from the Italian National Research Council, CNR, Progetto Finalizzato Oncologia No. 8600621.44 and 8502221.44. A. Melchiori is a recipient of a fellowship from Associazione Italiana per la Ricerca sul Cancro.

Received for publication 19 February 1987, and in revised form 25 June 1987.

References

1. Akiyama, S. K., S. S. Yamada, and K. M. Yamada. 1986. Characterization of a 140-kD avian cell surface antigen as a fibronectin-binding molecule. J. Cell Biol. 102:441-448.
2. Albinii, A., B. C. Adelmann-Grill, and P. K. Müller. 1985. Fibroblast chemotaxis. Collagen Relat. Res. 5:283-296.
3. Albinii, A., G. Allavena, H. Richter, B. F. Pontz, S. Parodi, and L. Santi. 1985. SV40-transformed fibroblasts recognize the same 140 kD fibronectin fragment as a non-transformed cells. Expertium (Basel). 41:1591-1593.
4. Albinii, A., G. Allavena, F. Giancotti, S. Parodi, H. Richter, and G. Tarone. 1986. Cell attachment and chemotaxis to fibronectin are mediated via the same cell surface receptor. J. Cell Biol. 103(5, Pt 2):254a. (Abstr.).
5. Albinii, A., H. Richter, and B. F. Pontz. 1983. Localization of the chemotactic domain in fibronectin. FEBS Lett. (Fed. Eur. Biochem. Soc.) J. 156:222-226.
6. Aswanikumar, S., B. A. Corcoran, E. Schiffmann, L. Day, R. J. Freer, H. J. Showell, E. L. Becker, and C. B. Pert. 1977. Demonstration of a receptor on rabbit neutrophils for chemotactic peptides. Biochem. Biophys. Res. Commun. 74:810-817.
7. Avery, R. L., and B. M. Glaser. Inhibition of cell migration by synthetic peptides. 1986. J. Cell Biol. 103(5, Pt 2):254a. (Abstr.).
8. Betsholtz, C., A. Johnson, C. Hedin, B. Westermark, P. Lind, M. S. Ueda, R. Edery, T. Shows, K. Phillips, A. L. Mellor, T. J. Knott, and J. Scoot. 1986. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines. Nature (Lond.). 320:695-699.
9. Brown, P., and R. L. Juliano. 1985. Selective inhibition of fibronectin-mediated cell adhesion by monoclonal antibodies to a cell-surface glycoprotein. Science (Wash. DC). 228:1448-1451.
10. Chen, J.-M., and W.-T. Chen. 1986. The 120K component of the 140K cell adhesion complex is essential for fibronectin receptor function on avian lung cells. J. Cell Biol. 103(5, Pt 2):534a. (Abstr.).
11. Chen, W.-T., J. M. Greve, D. I. Gottlieb, and S. J. Singer. 1985. The immunocytochemical localization of 140 kD cell adhesion molecules in cultured chicken fibroblasts and in chicken smooth muscle and intestinal epithelial tissues. J. Histochem. Cytochem. 33:576-586.
12. Chiang, T. M., A. E. Postlrettwaite, E. H. Beachey, J. M. Seyer, and A. H. Kang. 1978. Binding of chemotactic collagen-derived peptides to fibroblasts: the relationship to fibroblast chemotaxis. J. Clin. Invest. 62:916-922.
13. Damsky, C. H., K. A. Knudsen, D. Bradley, C. A. Buck, and A. P. Horwitz. 1985. Distribution of the CSAT cell matrix adhesion antigen on myogenic and fibroblastic cells in culture. J. Cell Biol. 100:1352-1359.
14. Donaldson, D. J., and J. T. Mahan. 1986. A synthetic peptide representing the fibroblast attachment site in fibronectin blocks migration of new epidermal cells over a variety of extracellular matrix proteins. J. Cell Biol. 103(5, Pt 2):534a. (Abstr.).
15. Duband, J. L., S. Rocher, W. T. Chen, K. M. Yamada, and J. P. Thiery. 1986. Cell adhesion and migration in the early vertebrate embryo: location and possible role of the putative fibronectin receptor complex. J. Cell Biol. 102:160-178.
16. Dziadek, M., H. Richter, M. Schachner, and R. Timpl. 1983. Monoclonal antibodies used as probes for the structural organization of the central region of fibronectin. FEBS (Fed. Eur. Biochem. Soc.) J. 135:321-325.
17. Gauss-Müller, V., H. K. Kleinman, G. R. Martin, and E. Schiffmann. 1980. Role of attachment factors and attractants in fibroblast chemotaxis. J. Exp. Med. 96:1071-1079.
18. Giancotti, F. G., P. M. Comoglio, and G. Tarone. 1986. A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion; immuno-fluorescence localization in normal and RSV-transformed fibroblasts. Exp. Cell Res. 163:97-42.
19. Giancotti, F., G. Tarone, K. Knudsen, C. Damsky, and P. M. Comoglio. 1985. Cleavage of a 135 kD cell surface glycoprotein correlates with loss of fibroblast adhesion to fibronectin. Exp. Cell Res. 156:182-190.
20. Giancotti, F., L. Languino, A. Zanetti, G. Peri, G. Tarone, and D. Edeana. 1987. Platelets express a membrane protein complex immunologically
related to the fibroblast fibronectin receptor and distinct from GPIIb/IIIa.

Blood. 69:1535–1538.

21. Greve, J. M., and D. I. Gottlieb. 1982. Monoclonal antibodies which alter the morphology of cultured chick myogenic cells. J. Cell. Biochem. 18: 221–229.

22. Grotendorst, G. R., and G. R. Martin. 1986. Cell movements in wound healing and fibrosis. Rheumatology. 10:385–403.

25. Horwitz, A., K. Duggan, R. Greggs, C. Decker, and C. Buck. 1985. The CSAT antigen has properties of a receptor for laminin and fibronectin. J. Cell Biol. 101:2134–2144.

26. Humphries, M., S. K. Akiyama, A. Komoriya, K. Olden, and K. Yamada. 1985. Characterization of a membrane glycoprotein complex implicated in cell adhesion to fibronectin. J. Cell. Biochem. 28:307–318.

27. Hynes, R. O., and K. M. Yamada. 1982. Fibronectins: multifunctional modular glycoproteins. J. Cell Biol. 95:369–377.

28. Lacovara, J., E. B. Cramer, and J. B. Quingley. 1984. Fibronectin enhancement of directed migration of B16 melanoma cells. Cancer Res. 44: 1657–1663.

29. Linsak, K. K., K. M. Yamada, and J. W. Lash. Effect of synthetic peptides of the fibronectin cell-binding region on chick precardiac cell migration. 1986. J. Cell Biol. 103S, Pt. 2:S35a. (Abstr.).

30. McCarthy, J. B., and L. T. Furcht. 1984. Laminin and fibronectin promote the haptotactic migration of B16 mouse melanoma cells in vitro. J. Cell Biol. 98:1474–1480.

31. McCarthy, J. B., M. Basara, S. L. Palm, D. F. Sas, and L. T. Furcht. 1985. The role of cell adhesion proteins—laminin and fibronectin—in the movement of malignant and metastatic cells. Cancer Metastasis Rev. 4: 125–152.

32. McCarthy, J. B., S. T. Hagen, and L. T. Furcht. 1986. Human fibronectin contains distinct adhesion- and motility-promoting domains for metastatic melanoma cells. J. Cell Biol. 102:179–187.

33. Mensing, H., A. Albini, T. Krieg, B. Pontz, and P. K. Müller. 1984. Enhanced chemotaxis of tumor-derived and virus-transformed cells to fibronectin and fibroblast-conditioned medium. Int. J. Cancer. 33:43–48.

34. Mensing, H., B. Pontz, P. K. Müller, and V. Gauss-Müller. 1983. A study of fibroblast chemotaxis using fibronectin and conditioned medium as chemotaxants. Eur. J. Cell Biol. 29:268–273.

35. Neff, N. T., C. Lowrey, C. Decker, A. Trovar, C. Damsky, C. Buck, and A. F. Horwitz. 1982. A monoclonal antibody detects embryonic skeletal muscle from extracellular matrices. J. Cell Biol. 95:654–666.

36. Niedel, J. E., I. Kahane, and P. Cuatrecasas. 1979. Receptor-mediated internalization of fluorescent chemotactic peptides by human polymorphonuclear neutrophilic leukocytes. 1980. Biochem. J. 192:517–525.

37. Pierschbacher, M. D., and E. Ruoslahti. 1984. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (Lond.) 309:30–33.

38. Pierschbacher, M. D., and E. Ruoslahti. 1984. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc. Natl. Acad. Sci. USA. 81:5985–5988.

39. Pierschbacher, M. D., E. G. Hayman, and E. Ruoslahti. 1981. Localization of the cell attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell. 26:259–267.

40. Pierschbacher, M. D., E. G. Hayman, and E. Ruoslahti. 1985. The cell attachment determinant in fibronectin. J. Cell. Biochem. 28:115–126.

41. Poslettwaite, A. E., J. Keski-Oja, G. Balian, and A. H. Kang. 1981. Induction of fibroblast chemotaxis by fibronectin: localization of the chemotactic region to a 140,000 molecular weight non-gelatin-binding fragment. J. Exp. Med. 153:494–499.

42. Poslettwaite, A. E., R. Snyderman, and A. H. Kang. 1976. Chemotactic attraction of human fibroblasts to a lymphocyte-derived factor. J. Exp. Med. 137:387–410.

43. Pytel, R., M. D. Pierschbacher, and E. Ruoslahti. 1985. Identification and isolation of a 140 Kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell. 40:191–198.

44. Rennard, S. I., G. W. Hunninghake, P. B. Bitterman, and R. G. Crystal. 1981. Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of injury in interstitial lung disease. Proc. Natl. Acad. Sci. USA. 78:7147–7151.

45. Richter, H., and H. Hörnmann. 1983. A large cpepsin-D-derived fragment from the central part of the fibronectin subunit chains. FEBS (Fed. Eur. Biochem. Soc.) Lett. 155:317–320.

46. Seppä, H., G. R. Grotendorst, S. Seppä, E. Schiffmann, and G. R. Martin. 1982. The platelet-derived growth factor is chemotactic for fibroblasts. J. Cell Biol. 92:584–588.

47. Seppä, H. E. J., K. M. Yamada, S. T. Seppä, M. H. Silver, H. K. Kleinman, and E. Schiffman. 1981. The cell-binding fragment of fibronectin is chemotactic for fibroblasts. Cell Biol. Int. Rep. 5:813–819.

48. Shosman, S. 1981. Wound healing. Int. Rev. Connect. Tissue Res. 9:1–26.

49. Snyderman, R., and E. J. Fudman. Demonstration of a chemotactic factor receptor on macrophages. 1980. J. Immunol. 124:2754–2757.

50. Tamkin, J. W., D. W. De Simo, D. Pond, R. S. Patel, C. Buck, A. F. Horwitz, and R. O. Hynes. 1986. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell. 46:271–282.

51. Tarone, G., G. Galletto, M. Prat, and P. M. Comoglio. 1982. Cell surface molecules and fibronectin-mediated cell adhesion: effect of proteolytic digestion of membrane proteins. J. Cell Biol. 94:179–186.

52. Tsukamoto, Y., W. E. Hewlsl, and S. M. Wahl. 1981. Macrophage production of fibronectin, a chemotaxant for fibroblasts. J. Immunol. 127:673–676.

53. Varani, J., and W. Ott. 1983. Chemotaxis in non-leukocytic cells. In Handbook of Inflammation. P. Ward, editor. Elsevier/North Holland, Amsterdam. 4:211–244.

54. Varani, J., and P. A. Ward. 1982. Tumor cell chemotaxis. In The Biological Basis of Metastasis. I. Hart, and L. Liotta, editors. Martinus Nijhoff, The Hague. 99–112.

55. Wang, J., C. Weinstock, T. Hasegawa, S. S. Yamada, K. M. Yamada, and W.-T. Chen. 1985. Altered organization of 140Kd putative ECM receptors in fibroblasts transformed by Rous sarcoma virus or treated with fibronectin cell-binding peptides. J. Cell Biol. 78:520–541.

56. Williams, L. T., R. Snyderman, M. C. Pike, and R. J. Lefkowitz. 1977. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc. Natl. Acad. Sci. USA. 74:1204–1208.

57. Zigmond, S. H., and J. G. Hirsch. 1973. Leukocyte locomotion and chemotaxis: new methods for evaluation and demonstration of a cell-derived chemotactic factor. J. Exp. Med. 137:387–410.